We are thrilled to announce ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer anjarium.com/otmane-boussif-…
Today we report that we have appointed Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive Director anjarium.com/press-release-1…
Anjarium retweeted
Schlieren biotech Anjarium unlocks the potential of gene therapy. In addition to top-tier investors supporting the idea, the company has obtained the Innosuisse Certificate, symbolising its readiness for growth. @AnjariumBio @Innosuisse startupticker.ch/en/news/sch…
We are thrilled to announce that we have raised CHF55.5M ($61M) Series A to develop our next-generation non-viral gene therapies.
The round was co-led by @Abingworthbio and @Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor (a Citadel company)
anjarium.com/10-16-21-anjari…
Anjarium retweeted
The first drug candidates harnessing exosomes as drug delivery systems for small molecules, DNA, RNA and other biologics are now entering clinical trials go.nature.com/378Pnoz - find out more about the burgeoning opportunities in the field in this news article by @megan_cully
Anjarium retweeted
We are ready for #BIODigital and super excited to present you our top-notch Swiss #biotech startups!
See you in Switzerland - where global pharma meets smart startups
#BIO2020 #SwissTech #SwissInnovation
@HofSwitzerland, @swisstech